NCT07051486: A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 60 planned
- Started
- 11 Oct 2025
- Primary completion
- Feb 2026
- Arms
- SHR-A1811 Group
- Results
- None posted
- 4 Jul 2025: Trial registered
- 11 Oct 2025: Trial started